RecruitingPhase 1Phase 2NCT05092685

Halting Ornithine Transcarbamylase Deficiency With Recombinant AAV in ChildrEn

Phase I/II Open Label, Multicentre Clinical Trial to Assess Safety and Efficacy of AAVLK03hOTC for Paediatric Patients With Ornithine Transcarbamylase Deficiency.

Sponsor

University College, London

Enrollment

12 participants

Start Date

Nov 1, 2023

Study Type

INTERVENTIONAL

Conditions

Ornithine Transcarbamylase Deficiency

Summary

Ornithine transcarbamylase deficiency (OTCD) is an inherited metabolic liver disease which means that the body cannot maintain normal levels of ammonia. Ammonia levels can rise (called hyperammonaemic decompensations) which can be life-threatening and may result in impaired neurological development in children. OTCD is a rare genetic disorder characterised by complete or partial lack of the enzyme ornithine transcarbamylase (OTC).

Eligibility

Min Age: 0 DaysMax Age: 16 Years

Inclusion Criteria9

Patient (male or female) aged ≤16 years at time of written informed consent. For the dose escalation phase patients must be aged 6-16, for the dose expansion phase patients must be aged 0-16 (at the time of written informed consent).
OTC deficiency confirmed via enzymatic or molecular analysis. This may include identification of pathogenic mutations or liver OTC activity that is \<20% of normal activity.
Patient has severe disease defined by reduced protein allowance and prescribed at least one ammonia scavenger drug.
Patient (if capable of signing) and parents or legal representative have signed a written informed consent form.
Females of childbearing potential must have a negative pregnancy test in serum or urine at the screening and Day 0 infusion visits, and use an adequate contraception method from the screening visit until 4 weeks after the first negative plasma sample monitoring vector genomes copies or the week 52 visit, whatever comes first.
Sexually active boys must use an adequate contraception method (abstinence or use of condom with spermicide) from at least 14 days prior to the infusion and until 4 weeks after the first negative plasma sample monitoring vector genomes copies or the week 52 visit, whatever comes first.
Patient's ammonia level at baseline visit (pre-gene therapy infusion) is \<100µmol/L and is within the range of historical ammonia levels obtained when the patient was clinically stable.
Patient has been on a stable dose of ammonia scavenger and stable protein allowance for the last 4 weeks at the baseline visit.
Patient is willing to commit to an additional 4 years of long-term safety follow-up.

Exclusion Criteria12

Titres of the neutralising antibodies against AAV-LK03 \>1:5 serum dilution.
Significant hepatic inflammation as evidenced by the following laboratory abnormalities: alanine aminotransferase or aspartate aminotransferase or bilirubin \>2 x upper limit of normal (ULN), alkaline phosphatase \>3 x ULN.
Evidence of severe unexplained liver disease including but not limited to liver malignancy, liver cirrhosis, or acute liver failure.
Evidence of active hepatitis B or C virus (HBV and HCV respectively) documented by hepatitis B surface antigen (HBsAg) or HCV RNA positivity.
Positive PCR for human immunodeficiency virus (HIV).
Liver transplant including hepatocytes/cells infusion.
Current participation in another clinical trial of an investigational medicinal product or medical device, or participation within previous 12 months.
Patient has contraindication to immunosuppression.
Active infection (bacterial or viral).
Pregnant or breastfeeding females.
Patients with other serious underlying medical conditions including malignancy and severe (≥ grade 3) functional organ impairment (liver, kidney, respiratory) according to CTCAE v5.0. For neurological symptoms considered as sequelae of previous hyperammonaemic decompensation and which are considered as stable (i.e. not evolving), a grade 3 will be acceptable. Grade 4 and 5 will preclude inclusion.
Patients with any other significant condition or disability that, in the investigator opinion, may interfere with the patient's optimal participation in the study.